Learn how medicines may affect sexual function, what to note before a medication review and why prescription changes belong in a clinician discussion.
In October 2026, the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) announced that information for certain antidepressants would warn that sexual dysfunction may continue after treatment stops. Medicines can affect sexual function for some people, but they are only one possible explanation for a change. That makes a medication review a place to raise concerns, not a reason to stop treatment on your own.
Sexual function is a broad term for experiences that include desire, arousal and physical responses. Desire means interest in sexual activity. Arousal refers to feeling sexually engaged or physically responsive.
For men, a change might involve getting or maintaining an erection. It might instead involve ejaculation or orgasm. Erectile dysfunction is a term for difficulty getting or maintaining an erection, rather than a label for every sexual concern.
These distinctions help make a concern easier to discuss. Reduced interest is a different description from wanting sexual contact but noticing an erection change. A person does not need medical vocabulary to explain that difference.
It can also help to describe what the change means in daily life. The main concern may be less enjoyment, uncertainty about what is happening or difficulty discussing it with a partner. That context belongs in the conversation alongside the physical symptom.
The European Association of Urology (EAU) describes erectile dysfunction as having several potential causes. These include vascular causes involving blood vessels and neurological causes involving nerves. Hormonal and psychological causes are also included.
The guideline lists associations with diabetes, hypertension and cardiovascular disease. It also includes obesity, smoking and medication use among relevant risk factors. Life stressors and other circumstances are part of the assessment.
The EAU lists thiazide diuretics and beta-blockers among antihypertensives associated with erectile dysfunction. Antihypertensives are medicines used to treat high blood pressure. An association means the medicine is worth considering during a review, not that its name alone establishes the cause.
The guideline reports adverse erectile effects with some cardiovascular medicines. It describes neutral or potentially beneficial effects with newer drugs. These findings do not identify a universal substitute or support treating every medicine in a class as equivalent.
The EAU also lists certain antidepressants, including selective serotonin reuptake inhibitors (SSRIs) and tricyclics, among medicines associated with erectile dysfunction. Mayo Clinic notes that some blood-pressure medicines and antidepressants can affect sexual function. It also names antihistamines and acid-blocking drugs.
For more background, Sexential’s discussion of medicines and male sexual response provides context for the questions a review can address.
The EAU recommends taking a comprehensive medical and sexual history when evaluating erectile dysfunction. That approach considers the sexual concern alongside health conditions and the medicines being used. It also makes room for life stressors rather than reducing the assessment to a prescription list.
Timing is useful information, but it is not proof of causation. A change noticed after starting a medicine may be relevant without settling the explanation. Health conditions, mental health and other medicines can also matter, as the EAU and Mayo Clinic discussions make clear.
The MHRA’s October 2026 announcement focused on improving information for patients taking antidepressants. It also advised clinicians to discuss possible sexual dysfunction when starting or changing antidepressant treatment, or at a later review. That makes the subject appropriate for an ordinary treatment discussion rather than something a patient must wait to be asked about.
The announcement does not establish how often persistent sexual dysfunction occurs. Its persistence warning concerns certain antidepressants and should not be extended to every medicine linked with sexual changes. Those are the boundaries of this safety update, not reasons to dismiss a concern.
A medication review also does not promise a change in treatment. Any possible adjustment needs to be considered alongside the condition the medicine treats. The practical goal is a better-informed discussion about both concerns.
Preparing notes is a way to organise the conversation, not a diagnostic test. The EAU’s emphasis on a full history supports bringing a clear account of the change and a complete medication list. The aim is to explain the concern in ordinary language.
A useful note separates the parts of sexual function rather than using one broad label. It might identify a change in desire or arousal. For another person, the concern may involve erections, ejaculation or orgasm.
If more than one aspect has changed, each can be described separately. Include how the change affects wellbeing or intimacy without trying to decide what it proves. This gives the clinician something more specific to discuss than a general worry about sexual performance.
Write down when the change became noticeable and how that timing relates to starting or changing a medicine. If the dates are uncertain, an approximate description is still a description rather than a conclusion. The purpose is to provide history, not to demonstrate that the prescription is responsible.
A brief record of changes and their context can help organise those observations. It is enough to note the pattern that prompted the question rather than turning each sexual experience into a test.
Include the full list of medicines and supplements being used. Keeping that information together reflects the broad medical history recommended by the EAU. A review should consider the whole list rather than focus only on the prescription that first attracted attention.
The list and the symptom description serve different purposes. One shows what is being used; the other explains what has changed. Together they help keep the discussion organised without asking the reader to make a diagnosis.
Alongside the medication list, note relevant health changes or life stressors you want the clinician to know about. The EAU includes contextual factors in assessment. The note can identify what else was happening around the time the sexual change began.
If explaining the concern aloud feels difficult, bringing the written account is another way to introduce it. The emphasis stays on what was noticed and what matters to the person seeking help.
An opening might be: I have noticed a change in sexual function and would like to review whether my medicines could be contributing. A follow-up could be: I also want to keep the condition being treated in view. These are conversation prompts, not claims about what caused the change.
Useful questions include:
If a partner is part of the conversation, the focus can stay on describing the change rather than assigning blame. Sexential’s discussion of talking about sex without keeping score offers relationship context for that conversation.
The MHRA advises patients who are concerned about sexual dysfunction while taking antidepressants to contact a healthcare professional. It explicitly advises against stopping antidepressants without first speaking to one. Raising the concern does not require deciding in advance that treatment must change.
A prescribing clinician can consider the sexual symptoms alongside the reason for treatment and the wider history. The review is the place to discuss whether any adjustment is appropriate. Stopping or changing a prescription independently is not a safe substitute for that discussion.
It is also reasonable to say if the change has affected confidence or made intimacy harder to discuss. Those effects are part of the concern being brought to the appointment, not evidence that a particular medicine caused it. Sexual wellbeing and care for the underlying condition belong in the same conversation.
The appointment can still be useful if no prescription change is made. A clearer account of the symptoms and relevant history gives the discussion a firmer starting point. The outcome to seek is an informed plan with the clinician, not a particular replacement medicine.
The October 2026 warning makes a possible sexual effect more visible. At a medication review, that information becomes a question about the whole person: how to take sexual wellbeing seriously while continuing to care for the condition being treated.
Sexual changes during medication use are observed by patients and assessed with their care team; Sexential adds accessible educational context. The publication addresses uncertainty about sexual function for adults aged 35 to 65 through calm explanations, helping them ask informed questions rather than select treatment on their own.
Follow Sexential for thoughtful guidance on desire, sexual function, hormones, confidence, relationships and intimacy. Explore new articles and evidence-aware resources for sexual wellbeing across adulthood.
A study reports more severe menopause symptoms among autistic women. Its self-reported findings raise questions about understanding and support.
An eight-week shatavari study reported sexual-function gains versus placebo. Read the findings, study limits and comparison with a different extract.
Changing desire, sleep and concentration deserve a care conversation. Read a clinician's argument alongside menopause guidance and its limits.
Explore practical resources on desire, function, hormones, confidence, intimacy and sexual wellbeing.
Read the Blog
